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Abstract 
Purpose: To employ meta-analysis to assess the effectiveness and adverse events of Xiyanping and 
ribavirin in children with rotavirus enteritis. 
Methods: Searches included PubMed, Embase, Medline, Cochrane Library, China National Knowledge 
Infrastructure (CNKI), China Biology Medicine Database (CBM), China Science and Technology Journal 
Database (VIP database), and Wanfang database from inception to March 2017. Clinical indicators, with 
respect to the total effectiveness rate, fever time, duration of diarrhea, creatinine kinase MB isoenzyme 
(CK-MB), rotavirus (RV) negative conversion rate, and adverse reaction, were compared between 
Xiyanping and ribavirin groups. 
Results: Five-hundred and twenty-six records were obtained after searching the databases, and 18 
studies (3557 participants) that met the inclusion criteria were included. All of them assessed total 
effectiveness rate, and two records evaluated RV negative conversion rate. There were significantly 
higher rates in the Xiyanping group than in the ribavirin group {OR = 3.76, 95 %CI (3.03 - 4.66), p < 
0.00001; OR = 2.68, 95 %CI (1.56 - 4.60), p = 0.0004}. Compared with ribavirin group, fever time, 
duration of diarrhea, and creatine kinase isoenzyme MB (CK-MB) were significantly lower in xiyanping 
group [MD = -1.23, 95 %CI (-1.64 to -0.81), p < 0.00001; MD= -2.15, 95 %CI (-2.68 to -1.62), p < 
0.00001; MD = -16.90, 95 %CI (-17.23 to -16.57), p < 0.00001}. Six studies reported adverse reactions, 
but there was no significant difference between xiyanping and ribavirin groups {OR = 1.44, 95 %CI (0.40 
- 5.17), p = 0.58}. 
Conclusion: This review suggests that xiyanping is more effective than ribavirin in children suffering 
from rotavirus enteritis. 
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Rotavirus (RV) causes acute vomiting, diarrhea, 
and fever, and is a major cause of enteritis in 
infants and children younger than 5 years of age, 
with an estimated 2 million hospitalizations and 
450,000 to 700,000 deaths worldwide per year 
[1]. RV was discovered in 1973 and is the main 
pathogen in infantile diarrhea in developing 
countries [2]. Rotavirus enteritis often occurs in 
autumn and winter in China [2]. The highest RV 
infection rate occurs in children at the age of 3 to 
5 y, and the greatest risk for developing severe 
disease that may negatively affect the respiratory 
system, myocardium, liver, kidneys, and nervous 
system occurs between 6 to 24 months of age 
[3,4]. In clinical settings, the treatment of 
rotavirus enteritis usually consists of dietary 
guidance, intestinal mucosa protector, micro-
ecological agents, and fluid therapy according to 
the situation, and may include cardiotonic, liver-
protecting, cough-relieving, and sputum-reducing 
measures. There are no unique antiviral drugs 
for RV enteritis in China, and ribavirin and 
Xiyanping injections are usually used. Xiyanping 
is a preparation derived from the herb 
Andrographis paniculata that is a water-soluble 
extract containingthe bitter principle 
andrographolide, which is a primary labdane 
diterpenoid. Xiyanping has been used in China 
for many years, as it possesses antibacterial, 
anti-inflammatory, and antiviral activities [5, 6]. 
Therefore, to derive a more precise evaluation on 
the effectiveness of ribavirin and Xiyanping in 







We undertook searches in order to identify 
relevant studies in the following databases: 
PubMed, Embase, Medline, the Cochrane library, 
CBM, CNKI, WanFang Database, and VIP 
Database. Searches for keywords included 
Xiyanping, andrographolide sulfonates, ribavirin, 
Virazole®, rotavirus enteritis, RV, and autumn 
diarrhea. 
 
Inclusion and exclusion criteria 
 
The following criteria had to be met in this meta-
analysis: (1) age range between 28 days and 18 
y; (2) randomized controlled trials (RCTs); (3) all 
subjects with rotavirus enteritis should fulfill the 
standard accepted diagnostic criteria with RV-
positive cases [7]; (4) two groups treated by 
Xiyanping or ribavirin (Xiyanping vs ribavirin) and 
the duration of medication above three days; (5) 
the outcome included the total effectiveness rate, 
fever time, duration of diarrhea, creatinine kinase 
MB isoenzyme (CK-MB), RV-negative 
conversion rate, or adverse reaction. Non-RCT 
studies, RV-negative or undetected studies, 
reviews of full text, conference abstracts, those 
with insufficient data for detailed analysis, and 
groups combined with other drugs, which 
influenced the results, were excluded.  
 
Selection of studies 
 
Liu and Jia independently screened each title 
and abstract of all retrieved studies meeting the 
inclusion criteria. A study was excluded when it 
did not relate to randomized controlled trials for 
pharmacological treatment of rotavirus enteritis in 
children and infants older than 28 days. 
Discrepancies were resolved by consensus; 
otherwise by the third author, Wang. 
 
Data extraction and management 
 
Liu and Wang separately extracted data from 
each included RCT using a data extraction form 
including the first author’ name and publication 
year, patients’ information, therapeutic methods 
and dosage, and the outcome measurements of 
interest. These data were entered into the 
Revman 5.3 software. In cases of disagreement, 




Cochrane Revman 5.3 software was employed 
for data analysis. For meta-analyses of 
dichotomous outcomes, dichotomous and 
continuous outcomes are presented as odds 
ratios (ORs) and standardized mean difference 
(SMD). I2 > 50 % denotes significant 
heterogeneity [8]. The fixed-effect model was 
used when I2 < 50 %. If the calculated I2 was 
greater than 50 %, random-effect and fixed-effect 




Search results and study characteristics 
 
On account of duplicate publication, non-RCTs, 
RV negative or undetected, or without included 
criteria, reviews, and conferences abstracts, 508 
studies were excluded and 18 studies were 
included (Figure 1). Among the included studies, 
18 studies [9-26] reported the total effectiveness 
rate, four studies [11,14,20,25] evaluated fever 
time, 4 studies [10,11,14,20] related the duration 
of diarrhea, 3 studies [13,17,22] reported CK-MB, 
2 studies were related to the RV-negative 
conversion rate (RSV) [17,22], and six studies  
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Figure 1: Study flow 
 
[11,14,19-21,26] described adverse reactions. 
The basic characteristics of the selected studies 
are summarized in Table 1. 
 
Risk of bias in included studies 
 
Assigning categories of high risk/ unclear risk/ 
low risk are presented in Figure 2A and Figure 
2B for each included studies. 
 
Total effectiveness rate 
 
Eighteen articles, without significant 
heterogeneity (I2 = 0 %), reported the total 
effectiveness rate (Figure 3A), and were 
analyzed by the fixed-effect model. The 
xiyanping group was significantly higher than the 
ribavirin group {OR=3.76, 95 % CI (3.03-4.66); 
Z=12.06, p < 0.00001; Figure 3A} in the total 
effectiveness rate. 
 
Fever time and duration of diarrhea 
 
The fever time and duration of diarrhea in the 
Xiyanping group were significantly lower as 
compared to the ribavirin group [MD= -1.23, 95 
% CI (-1.64～-0.81); Z=5.80, p<0.00001 and 
MD= -2.15, 95%CI (-2.68～ -1.62); Z=7.98, 
p<0.00001; Figure3B and Figure 3C}. The 
random-effect model was used because there 
was marked heterogeneity among the studies 
above. 
 
CK-MB and RV-negative conversion rate 
 
Xiyanping obviously decreased the value of CK-
MB compared with ribavirin {MD=-16.90, 95%CI 
(-17.23～ -16.57); Z=100.98, p<0.00001; 
Figure4A}, with low heterogeneity (p = 0.57, I2 = 
0%). Two articles reported the RV-negative 
conversion rate, and the Xiyanping group was 
significantly higher than the ribavirin group 
{OR=2.68, 95%CI (1.56～4.60); Z=3.57, 
p=0.0004; Figure4B}; these articles were 





Six studies, without heterogeneity [p = 0.91, I2 = 
0%], reported the adverse reaction of Xiyanping 
and ribavirin in rotavirus enteritis, and were 
analyzed by the fixed-effect model. There were 
no adverse reactions in four of them, whereas  
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Table 1: Baseline characteristics of included studies 
 
Study Cases (T/C) Intervention Outcome indicator 
Chen, (2011) [10] 36/32 T: Xiyanping injection, IV, 5-10mg/(mg·d) once daily 
C: Ribavirin injection, IV, 10mg/(mg·d) once daily 
(1) (3) 
Chen, (2015) [14] 60/60 T: Xiyanping injection, IV, 5-10mg/(mg·d) once daily 
C: Ribavirin injection, IV, 10-15mg/(mg·d) once daily 
(1) (2) (3) (6) 
Deng, (2014) [15] 40/40 T: Xiyanping injection, IV, 5mg/(mg·d) once daily 
C: Ribavirin injection, IV, 10-15mg/(mg·d) once daily 
(1) (3) 
Huang, (2017) [11] 50/50 T: Xiyanping injection, IV, 10mg/(mg·d) once daily 
C: Ribavirin injection, IV, 10mg/(mg·d) once daily 
(1) (2) (3) (4) (6) 
Jiang, (2013) [9] 960/880 T: Xiyanping injection, IV, 5mg/(mg·d) once daily 
C: Ribavirin injection, IV, 10mg/(mg·d) once daily 
(1) 
Liu, (2004) [16] 74/48 T: Xiyanping injection, IV, 5mg/(mg·d) once daily 
C: Ribavirin injection, IV, 10mg/(mg·d) once daily 
(1) 
Liu, (2008) [12] 35/35 T: Xiyanping injection, IV, 5mg/(mg·d) once daily 
C: Ribavirin injection, IV, 5-10mg/(mg·d) once daily 
(1) 
Shi,  (2011) [13] 40/40 T: Xiyanping injection, IV, 5mg/(mg·d) once daily 
C: Ribavirin injection, IV, 10-15mg/(mg·d) once daily 
(1) (4) 
Xu,  (2012) [17] 47/54 T: Xiyanping injection, IV, 7.5mg/(mg·d) once daily 
C: Ribavirin injection, IV, 10mg/(mg·d) once daily 
(1) (4) (5) 
Zeng, (2012) [18] 45/45 T: Xiyanping injection, IV, 5mg/(mg·d) once daily 
C: Ribavirin injection, IV, 10-15mg/(mg·d) once daily 
(1) 
Zhang, (2011) [19] 40/40 T: Xiyanping injection, IV, 5-10mg/(mg·d) once daily 
C: Ribavirin injection, IV, 5-10mg/(mg·d) once daily 
(1) (6) 
Zhang, (2013) [20] 170/90 T: Xiyanping injection, IV, 5mg/(mg·d) once daily 
C: Ribavirin injection, IV, 10mg/(mg·d) once daily 
(1) (2) (3) (6) 
Zhang, (2014) [21] 37/35 T: Xiyanping injection, IV, 5-10mg/(mg·d) once daily 




68/60 T: Xiyanping injection, IV, 7.5mg/(mg·d) once daily 
C: Ribavirin injection, IV, 10mg/(mg·d) once daily 
(1) (4) (5) 
Zhaoxiaoyan, 
(2015) [23] 
21/21 T: Xiyanping injection, IV, 5mg/(mg·d) once daily 
C: Ribavirin injection, IV, 10-15mg/(mg·d) once daily 
(1) 
Zhong, (2009) [24] 48/40 T: Xiyanping injection, IV, 5-10mg/(mg·d) once daily 
C: Ribavirin injection, IV, 10mg/(mg·d) once daily 
(1) 
Zhou, (2012) [25] 60/60 T: Xiyanping injection, IV, 5-10mg/(mg·d) once daily 
C: Ribavirin injection, IV, 10-15mg/(mg·d) once daily 
(1) (2) 
Zhou, (2013) [26] 48/48 T: Xiyanping injection, IV, 5-10mg/(mg·d) once daily 
C: Ribavirin injection, IV, 10-15mg/(mg·d) once daily 
(1) (6) 
Note: (1) The total effectiveness rate; (2) Fever time; (3) Duration of diarrhea; (4) CK-MB; (5) RV-negative 
conversion rate; (6) Adverse reaction 
 
skin rashes, leukopenia, and diarrhea were 
reported in the other two studies. The results 
indicate that skin rashes, leucopenia, and 
diarrhea symptoms were without significant 
difference in the two groups {OR=1.44, 95%CI 




Publication bias is graphically represented by 
funnel plots in Figure 5, which shows no 




The main ingredient of Xiyanping is 
andrographolide, a diterpenoid lactone from 
Andrographis paniculata, which is a traditional 
medicinal herb of the Acanthaceae family that 
has been widely cultivated in China, India, 
Thailand, and other Asian countries for 
centuries. Andrographolide is well known for 
its anti-inflammatory effects under various 
conditions such as cancer and malaria, its anti-
viral action against infections of the upper 
respiratory tract and intestinal tract, and its 
immunomodulatory effects whereby it 
enhances the expression of cytotoxic T cells 
and natural killer cells and promotes 
phagocytosis and antibody-dependent cell-
mediated cytotoxicity [27-31]. 
 
Andrographolide showed potential antibacterial 
activity against most Gram-positive bacteria 
and Gram-negative bacteria, such as 
Staphylococcus aureus, Streptococcus 
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Figure 2: A = risk of bias graph: each risk of bias item presented as percentages across all included studies. B = 
risk of bias summary: each risk of bias item for each included studies 
 
pneumonia, and Escherichia coli [31]. Apart from 
its antibacterial activity, andrographolide can 
inhibit viral replication and induce viral 
destruction in pathogens such as influenza A 
virus (IAV), hepatitis virus, herpes simplex virus 
(HSV), Epstein-Barr virus (EBV), human 
papillomavirus (HPV) [28]. Seubsasana et al 
showed that andrographolide exhibits anti-
replication activity and decreases the expression 
of gpC and gpD throughout treatment, although it 
was able to inhibit HSV entry by less than 50 % 
[32]. Chang et al [33] found that andrographolide 
cannot directly inhibit viruses, but inhibits virus-
induced cell signaling dysregulation, which 
results in an increase in CD4+ lymphocytes [33]. 
 
In this systematic review, we reviewed the data 
from 18 comparisons, involving 3557 patients 
with rotavirus enteritis, and we made several 
important observations. The major findings of this 
meta-analysis are that the total effectiveness rate 
was significantly higher for Xiyanping as 
compared to ribavirin. The study suggested that 
Xiyanping shortens the fever time and duration of 
diarrhea, lowers the value of CK-MB, and 
increases the RV-negative conversion rate 
compared with ribavirin. In addition, adverse 
reactions were equal in the two groups. 
 
One meta-analysis found that Xiyanping was 
equally effective as ribavirin in the treatment of 
patients with RV enteritis [3]. However, those 
authors searched from January 2003 to 
December 2013 in four databases and only one 
outcome indicator. Therefore, the article 
analyzed published RCTs to evaluate the role of 
Xiyanping in RV enteritis, comparing the efficacy 
and safety with ribavirin. No publication bias 





The current study has the following limitations. 
Firstly, the quality of the studies was not high, 
and the participants were all Chinese. There was  
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Figure 3: Forest plot of comparison of the total effectiveness rate (A), the fever time (B), and diarrhea duration 
(C) of Xiyanping versus ribavirin in rotavirus enteritis 
 
a lack of other high-quality studies in other 
languages and a lack of multi-center randomized 
clinical trials. In future research, it is necessary 
that the efficacy and safety of Xiyanping be 
proven in other races. Secondly, only three 
articles described the random methods used, 
and one mentioned blindness but without 
methodology, but no trial explained the allocation 
concealment method. Finally, we have not yet 
analyzed reasons, why the heterogeneity of 
Figure 3B reduced to 0% when the study by 
Zhou in 2012 was removed. Thus, the random-
effect model was selected. Future research 





This review suggests that Xiyanping is more 
effective than ribavirin for RV enteritis, based on 
the included RCTs. The antiviral activity of 
andrographolide has been demonstrated in many 
virus infections, and thus has the potential for 
being developed as a new highly potent antiviral 
drug with multiple effects. However, further 
analyses with larger samples and other races are 
needed to confirm the efficacy and safety of 
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Figure 4: Forest plot of comparison of CK-MB (A), RV-negative (B), and the adverse reaction (C) of Xiyanping 




Figure 5: Funnel plot for the total effective rate 
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